Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACTTM (Hyaluronic Acid Chemotransport Technology) platform which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACTÔ platform is HyCAMPÔ. In addition to HyCAMPTM, Meditech has taken the anti-cancer products HyDOXTM (doxorubicin and hyaluronic acid) and HyFIVETM (5-fluorouracil and hyaluronic acid) into clinical testing.
View Top Employees from MIS.CARBONART| Website | https://www.mrl.com.au |
| Revenue | $14 million |
| Employees | 5 (5 on RocketReach) |
| Address | Carbonart, Bibra Lake, Western Australia 6063, AU |
| Phone | +61 3 9296 2026 |
| Industry | Research, Biotechnology, Pharmaceuticals, Healthcare |
| Competitors | Aspyrian Therapeutics, Inc, Constellation Pharmaceuticals, A MorphoSys Company, ORIC Pharmaceuticals Inc., Xintela AB, Ziopharm Oncology Limited |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular MIS.CARBONART employee's phone or email?
MIS.CARBONART Questions
The MIS.CARBONART annual revenue was $14 million in 2024.
5 people are employed at MIS.CARBONART.
MIS.CARBONART is based in Bibra Lake, Western Australia.
The NAICS codes for MIS.CARBONART are [54, 5417, 541].
The SIC codes for MIS.CARBONART are [87, 873].
Top MIS.CARBONART Employees
Related Companies
